In a filing, Gilead Sciences, Inc. revealed its Chief Medical Officer Parsey Merdad unloaded Company’s shares for reported $0.17 million on Oct 01 ’24. In the deal valued at $83.83 per share,2,000 shares were sold. As a result of this transaction, Parsey Merdad now holds 100,189 shares worth roughly $8.65 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, MERDAD V PARSEY bought 2,000 shares, generating $167,660 in total proceeds.
Before that, Parsey Merdad sold 21,246 shares. Gilead Sciences, Inc. shares valued at $1,795,287 were divested by the Chief Medical Officer at a price of $84.50 per share. As a result of the transaction, Parsey Merdad now holds 102,189 shares, worth roughly $8.82 million.
Leerink Partners upgraded its Gilead Sciences, Inc. [GILD] rating to an Outperform from a a Market perform in a research note published on October 21, 2024; the price target was increased to $96 from $74. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in mid October with a ‘”an Outperform”‘ rating. Wells Fargo also remained covering GILD and has increased its forecast on October 07, 2024 with a “an Overweight” recommendation from previously “an Equal weight” rating. Raymond James revised its rating on July 08, 2024. It rated GILD as “an Outperform” which previously was an “a Mkt perform”.
Price Performance Review of GILD
On Monday, Gilead Sciences, Inc. [NASDAQ:GILD] saw its stock fall -0.50% to $86.29. Over the last five days, the stock has gained 1.46%. Gilead Sciences, Inc. shares have risen nearly 6.52% since the year began. Nevertheless, the stocks have risen 10.01% over the past one year. While a 52-week high of $87.86 was reached on 01/19/24, a 52-week low of $62.07 was recorded on 05/31/24. SMA at 50 days reached $81.20, while 200 days put it at $74.04.
Levels Of Support And Resistance For GILD Stock
The 24-hour chart illustrates a support level at 85.72, which if violated will result in even more drops to 85.14. On the upside, there is a resistance level at 87.07. A further resistance level may holdings at 87.84. The Relative Strength Index (RSI) on the 14-day chart is 63.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.30, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 29.89%. Stochastics %K at 81.62% indicates the stock is a selling.
How much short interest is there in Gilead Sciences, Inc.?
A steep rise in short interest was recorded in Gilead Sciences, Inc. stocks on 2024-09-30, dropping by -2.06 million shares to a total of 17.74 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 19.8 million shares. There was a decline of -11.63%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 01, 2024 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $85.
